KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Amortization of Deferred Charges: 2017-2025

Historic Amortization of Deferred Charges for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $2.7 million.

  • Aquestive Therapeutics' Amortization of Deferred Charges rose 2.81% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 12.06%. This contributed to the annual value of $10.7 million for FY2024, which is 443.31% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Amortization of Deferred Charges is $2.7 million, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Amortization of Deferred Charges peaked at $2.8 million during Q1 2025, and registered a low of $40,000 during Q1 2022.
  • Its 3-year average for Amortization of Deferred Charges is $2.3 million, with a median of $2.7 million in 2024.
  • Per our database at Business Quant, Aquestive Therapeutics' Amortization of Deferred Charges plummeted by 96.62% in 2022 and then soared by 2,920.69% in 2023.
  • Aquestive Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $127,000 in 2021, then tumbled by 54.33% to $58,000 in 2022, then soared by 2,920.69% to $1.8 million in 2023, then soared by 54.05% to $2.7 million in 2024, then increased by 2.81% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.8 million during Q1 2025.